Top Markets
Coin of the day
Pell Bio-Med Technology Co., Ltd. Pell Bio-Med Technology Co., Ltd.

Pell Bio-Med Technology Co., Ltd.

6949
Peringkat dalam Saham #4978
Pell Bio-Med Technology Co., Ltd., established in 2017 and headquartered in... Pell Bio-Med Technology Co., Ltd., established in 2017 and headquartered in Taipei, Taiwan, operates as a biomedical firm specializing in advanced cell culture technologies and methods for therapeutic applications. The company's commercial portfolio encompasses good tissue practice (GTP) laboratory infrastructure, adipose-derived stem cells (ADSC) utilized in regenerative medicine, and both CIK and DC-CIK therapies aimed at combating various cancers. Beyond its existing products, Pell Bio-Med is actively engaged in developing novel pharmaceuticals for diverse cancer types, pioneering cell immunotherapy strategies, and advancing stem cell regenerative therapy techniques. Its research and development efforts extend to cutting-edge areas such as chimeric antigen receptor T cell (CAR-T), CAR-NK, CAR-?dT, and genetically modified ADSC technologies. The company is also progressing product development specifically targeting indications like B-cell non-Hodgkin lymphoma (B-NHL), ovarian cancer, multiple myeloma, and thyroid cancer.
Harga Saham
$47.38
Terakhir disinkronkan: 2026-08-26
Kapitalisasi Pasar
$3.11B
Perubahan (1 hari)
9.96%
Perubahan (1 tahun)
238.59%
Negara
TW
Perdagangan Pell Bio-Med Technology Co., Ltd. (6949)

Kategori

Riwayat hasil dividen untuk Pell Bio-Med Technology Co., Ltd. (6949)
Hasil dividen (TTM) dari Pell Bio-Med Technology Co., Ltd. (simbol saham: 6949) per 2026: 0
Rata-rata hasil dividen selama 5 tahun terakhir: 0.00%
Riwayat hasil dividen untuk Pell Bio-Med Technology Co., Ltd. (6949) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
Tahun Hasil Dividen Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Hasil dividen (TTM) untuk perusahaan serupa atau pesaing
Perusahaan Hasil Dividen Negara
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH